Patents by Inventor Seth Rubin

Seth Rubin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12264339
    Abstract: The disclosure provides polypeptides comprising an engineered p27, or a fragment thereof such polypeptides may be used to form trimeric protein complexes with a cyclin-dependent kinase 4 (Cdk4) (or a variant thereof) or Cdk6 (or a variant thereof), and a cyclin D (CycD) or a variant thereof.
    Type: Grant
    Filed: May 16, 2023
    Date of Patent: April 1, 2025
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Seth Rubin, Keelan Guiley
  • Publication number: 20230407274
    Abstract: The disclosure provides polypeptides comprising an engineered p27, or a fragment thereof such polypeptides may be used to form trimeric protein complexes with a cyclin-dependent kinase 4 (Cdk4) (or a variant thereof) or Cdk6 (or a variant thereof), and a cyclin D (CycD) or a variant thereof.
    Type: Application
    Filed: May 16, 2023
    Publication date: December 21, 2023
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Seth RUBIN, Keelan GUILEY
  • Patent number: 11692179
    Abstract: The disclosure provides polypeptides comprising an engineered p27, or a fragment thereof. Such polypeptides may be used to form trimeric protein complexes with a cyclin-dependent kinase 4 (Cdk4) (or a variant thereof) or Cdk6 (or a variant thereof), and a cyclin D (CycD) or a variant thereof.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: July 4, 2023
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Seth Rubin, Keelan Guiley
  • Publication number: 20220411471
    Abstract: Cyclic peptides that inhibit MDM2 or MDM2 and MDM4, pharmaceutical compositions containing these cyclic peptides, and methods of using these cyclic peptides for inhibiting MDM2 or MDM2 and MDM4 are described herein.
    Type: Application
    Filed: May 20, 2022
    Publication date: December 29, 2022
    Inventors: Cameron PYE, Joshua SCHWOCHERT, Seth RUBIN, Anthony SILVESTRI
  • Publication number: 20210002619
    Abstract: The disclosure provides polypeptides comprising an engineered p27, or a fragment thereof. Such polypeptides may be used to form trimeric protein complexes with a cyclin-dependent kinase 4 (Cdk4) (or a variant thereof) or Cdk6 (or a variant thereof), and a cyclin D (CycD) or a variant thereof.
    Type: Application
    Filed: April 10, 2019
    Publication date: January 7, 2021
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Seth RUBIN, Keelan GUILEY
  • Patent number: 9573977
    Abstract: A method for preventing neoplastic transformation by inhibition of cell cycle progression into S phase by preventing the inactivation of Retinoblastoma protein (Rb).
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: February 21, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Jason Burke, Seth Rubin
  • Publication number: 20160257717
    Abstract: A method for preventing neoplastic transformation by inhibition of cell cycle progression into S phase by preventing the inactivation of Retinoblastoma protein (Rb).
    Type: Application
    Filed: May 5, 2016
    Publication date: September 8, 2016
    Applicant: The Regents of the University of California
    Inventors: Jason Burke, SETH RUBIN
  • Patent number: 9365621
    Abstract: A method for preventing neoplastic transformation by inhibition of cell cycle progression into S phase by preventing the inactivation of Retinoblastoma protein (Rb).
    Type: Grant
    Filed: April 12, 2013
    Date of Patent: June 14, 2016
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Jason Burke, Seth Rubin
  • Publication number: 20150259384
    Abstract: A method for preventing neoplastic transformation by inhibition of cell cycle progression into S phase by preventing the inactivation of Retinoblastoma protein (Rb).
    Type: Application
    Filed: April 12, 2013
    Publication date: September 17, 2015
    Inventors: Jason Burke, Seth Rubin
  • Publication number: 20040062715
    Abstract: A functionalized active-nucleus complex sensor that selectively associates with one or more target species. The functionalized active-nucleus complex comprises an active-nucleus and a targeting carrier. The targeting carrier comprises a first binding region having at least a minimal transient binding of the active-nucleus to form the functionalized active-nucleus complex that produces a detectable signal when the functionalized active-nucleus complex associates with the target species and a second binding region that selectively associates with the target species. Included is a method for assaying and screening for one or a plurality of target species utilizing one or a plurality of functionalized active-nucleus complexes with at least two of the functionalized active-nucleus complexes having an attraction affinity to different corresponding target species.
    Type: Application
    Filed: September 15, 2003
    Publication date: April 1, 2004
    Inventors: Alexander Pines, David E. Wemmer, Megan Spence, Seth Rubin
  • Patent number: 6652833
    Abstract: A functionalized active-nucleus complex sensor that selectively associates with one or more target species, and a method for assaying and screening for one or a plurality of target species utilizing one or a plurality of functionalized active-nucleus complexes with at least two of the functionalized active-nucleus complexes having an attraction affinity to different corresponding target species. The functionalized active-nucleus complex has an active-nucleus and a targeting carrier. The method involves functionalizing an active-nucleus, for each functionalized active-nucleus complex, by incorporating the active-nucleus into a macromolucular or molecular complex that is capable of binding one of the target species and then bringing the macromolecular or molecular complexes into contact with the target species and detecting the occurrence of or change in a nuclear magnetic resonance signal from each of the active-nuclei in each of the functionalized active-nucleus complexes.
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: November 25, 2003
    Assignee: The Regents of the University of California
    Inventors: Alexander Pines, David E. Wemmer, Megan Spence, Seth Rubin
  • Patent number: 6654009
    Abstract: A method for arranging entities in a two-dimensional lattice including the steps of determining all applicable two-dimensional lattice forms from a predetermined group of lattice forms for a predetermined number of entities to be arranged; determining the dimensions of a bounding region and a uniform separation distance between a center point of each entity for each applicable lattice form; selecting an optimal applicable two-dimensional lattice form; and plotting positions of each of the predetermined number of entities within the optimal applicable two-dimensional lattice form.
    Type: Grant
    Filed: May 23, 2001
    Date of Patent: November 25, 2003
    Inventor: Seth Rubin
  • Publication number: 20030165431
    Abstract: An active-nucleus sensor or a functionalized active-nucleus complex sensor is utilized in a method for detecting conformational change and binding event information in a targeted molecule, wherein the sensor does not participate in the conformational change or binding event. The method directly or indirectly detects the occurrence, deletion, shift, or any measurable change in a magnetic resonance signal with a unique magnetic resonance property from the active-nuclei, frequently hyperpolarized 129Xe.
    Type: Application
    Filed: October 9, 2002
    Publication date: September 4, 2003
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Alexander Pines, David E. Wemmer, Megan Spence, Seth Rubin, E. Janette Ruiz, Ivan E. Dimitrov
  • Publication number: 20020037253
    Abstract: A functionalized active-nucleus complex sensor that selectively associates with one or more target species, and a method for assaying and screening for one or a plurality of target species utilizing one or a plurality of functionalized active-nucleus complexes with at least two of the functionalized active-nucleus complexes having an attraction affinity to different corresponding target species. The functionalized active-nucleus complex has an active-nucleus and a targeting carrier. The method involves functionalizing an active-nucleus, for each functionalized active-nucleus complex, by incorporating the active-nucleus into a macromolucular or molecular complex that is capable of binding one of the target species and then bringing the macromolecular or molecular complexes into contact with the target species and detecting the occurrence of or change in a nuclear magnetic resonance signal from each of the active-nuclei in each of the functionalized active-nucleus complexes.
    Type: Application
    Filed: July 11, 2001
    Publication date: March 28, 2002
    Applicant: The Reagents of the University of California
    Inventors: Alexander Pines, David E. Wemmer, Megan Spence, Seth Rubin
  • Publication number: 20010048433
    Abstract: A method for arranging entities in a two-dimensional lattice including the steps of determining all applicable two-dimensional lattice forms from a predetermined group of lattice forms for a predetermined number of entities to be arranged; determining the dimensions of a bounding region and a uniform separation distance between a center point of each entity for each applicable lattice form; selecting an optimal applicable two-dimensional lattice form; and plotting positions of each of the predetermined number of entities within the optimal applicable two-dimensional lattice form.
    Type: Application
    Filed: May 23, 2001
    Publication date: December 6, 2001
    Inventor: Seth Rubin